STOCK ISSUANCE AGREEMENTStock Issuance Agreement • October 8th, 2024 • Immunome Inc. • Pharmaceutical preparations • Delaware
This Stock Issuance Agreement (“Agreement”) is entered into as of August 7, 2024, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”), and Immunome, Inc., a Delaware corporation having an office at 18702 N. Creek Parkway, Suite 100, Bothell, Washington 98011 (“Immunome”). Immunome and BMS are together referred to in this Agreement as the “Parties” and individually as a “Party.”
